MabThera/Rituxan

Venclexta plus Gazyva approval adds to non-chemo options in CLL

One example of that is academic research networks who are carrying out their own research of the new agents in combination with Gazyva’s successor treatment, Roche’s off-patent ... Rituxan (rituximab).

Roche and NHS England hail pricing deal on MS drug Ocrevus

The approval is good news for Roche, as Ocrevus is one of its most important new products, much needed as its trio of older cancer blockbusters – Avastin, MabThera and Herceptin – go

Hemlibra off to a flyer as Roche raises 2019 forecasts

There was some slippage for immunology drug MabThera/Rituxan (rituximab) and Herceptin (trastuzumab) for breast cancer, with the declines seen most starkly in Europe where they fell 38% and 44% respectively.

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

R2 met its primary endpoint of PFS in trials. The FDA has begun a priority review of Celgene’s blood cancer blockbuster Revlimid in combination with Roche’s Rituxan as a ... of non-Hodgkin’s lymphoma), but failed to show any benefit in these

Pfizer closes on EU approval of lung cancer drug Vizimpro

Meanwhile, Sanofi picked up new labelling for cholesterol-lowering antibody Praluent (alirocumab) that included a cardiovascular risk reduction claim, while Roche’s venerable antibody drug MabThera (rituximab) added the new indication

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]